表皮生长因子受体在头颈部癌症中的预后作用：一项荟萃分析。

Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis.

机构信息

Department of Otorhinolaryngology, Peking Union Medical College Hospital, Beijing, PR China.

出版信息

J Surg Oncol. 2013 Nov;108(6):387-97. doi: 10.1002/jso.23406. Epub 2013 Sep 13.

DOI:10.1002/jso.23406

PMID:24038070

Abstract

BACKGROUND AND OBJECTIVES

To evaluate the predicting value of the epidermal growth factor receptor (EGFR) for survival in patients with head and neck cancer (HNC).

METHODS

Data were collected from studies comparing overall survival (OS) or progression-free survival (PFS) in patients with higher or lower EGFR levels. Studies were pooled and combined hazard ratios (HRs) of EGFR for survival were calculated.

RESULTS

A total of 68 studies involving 6,781 patients were included for meta-analysis. Either EGFR protein expression or gene copy number had prognostic value in HNC patients. EGFR overexpression could predict worse outcome, with HRs of 1.65 (95% CI: 1.45, 1.86) for OS and 1.27 (95% CI: 1.17, 1.37) for PFS. Increased EGFR copy number was also associated with reduced survival, with HRs of 1.5 (95% CI: 1.15, 1.96) for OS and 1.35 (95% CI: 1.14, 1.61) for PFS. Furthermore, EGFR overexpression could predict poorer OS in both eastern and western countries. Particularly, EGFR was considered a strong predictor in laryngeal squamous cell cancer (HR > 2).

CONCLUSION

Elevated EGFR expression and gene copy number could predict poor survival in HNC patients.

摘要

背景与目的

评估表皮生长因子受体（EGFR）在头颈部癌症（HNC）患者生存预测中的价值。

方法

从比较 EGFR 水平较高或较低的患者总生存率（OS）或无进展生存率（PFS）的研究中收集数据。对研究进行合并，并计算 EGFR 对生存的合并危险比（HRs）。

结果

共有 68 项研究纳入了 6781 例患者进行荟萃分析。EGFR 蛋白表达或基因拷贝数在 HNC 患者中均具有预后价值。EGFR 过表达可预测更差的预后，OS 的 HR 为 1.65（95%CI：1.45，1.86），PFS 的 HR 为 1.27（95%CI：1.17，1.37）。EGFR 拷贝数增加也与生存降低相关，OS 的 HR 为 1.5（95%CI：1.15，1.96），PFS 的 HR 为 1.35（95%CI：1.14，1.61）。此外，EGFR 过表达可预测东西方国家的 OS 更差。特别是，EGFR 被认为是喉鳞状细胞癌（HR>2）的一个强有力的预测因子。